Developmental Therapeutics, Immunotherapy

ABSTRACTS

*Duke authors bolded

Brent Hanks, MD, PhD, is the Discussant at the Clinical Science Symposium “Systems Biology Approaches to Immunotherapy Response and Toxicity” presentation entitled ‘Rise of the Machines: AI in Predicting Immunotherapy Outcomes’.

Landon Carter Brown, MD, will be presented with a Conquer Cancer ASCO Merit Award for his abstract (Abstract 3007) "Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types." He will deliver an oral presentation of his abstract at the annual meeting. Mentored by Andrew Armstrong, MD, MSc, Brown's research suggests that a subset of patients with LRP1B mutations may be more sensitive to immunotherapy. Per the study abstract conclusions: "This multicenter study shows impressive and durable objective response rates to ICI for patients harboring pathogenic LRP1B alterations when compared to those with LRP1B VUS, independent of TMB/MSI status. Further mechanistic insights and prospective validation studies are warranted."   [Read More]
AUTHORS: Landon Carter Brown, Ramy Sedhom, Eric B Schwartz, Jason Zhu, Chester Kao, Matthew D Tucker, Matthew Labriola, Rajan T. Gupta, Daniele Marin, Yuan Wu, Tian Zhang, Michael Roger Harrison, Daniel J. George, Ajjai Shivaram Alva, Emmanuel S. Antonarakis, Andrew J. Armstrong

ABSTRACTS

Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events.
SESSION
Developmental Therapeutics—Immunotherapy
AUTHOR(S)
David E. Kozono, Elad Sharon, Jennifer Le-Rademacher, Erin Twohy, Tyler J. Zemla, Yujia Wen, Mark Watson, Elie G. Dib, John M. Kirkwood, Gary H. Lyman, Jarushka Naidoo, Andrew B. Nixon, Elizabeth A. Mittendorf
ABSTRACT / POSTER TPS3154 ● 218

Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.
SESSION
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
AUTHOR(S)
Martin Gutierrez, Vivek Subbiah, John J. Nemunaitis, Niharika B. Mettu, Kyriakos P. Papadopoulos, Minal A. Barve, Luis Féliz, Christine Francis Lihou, Chenwei Tian, Tao Ji, Ian M. Silverman, Rashmi Chugh, Mansoor N. Saleh
ABSTRACT / POSTER 3606 ● 336

Circulating stromal cells as a potential blood-based biomarker for screening invasive solid tumors.
SESSION
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
AUTHOR(S)
Daniel Adams, Steven H. Lin, Harvey I. Pass, Saranya Chumsri, Rena G. Lapidus, Martin Edelman, Raymond C. Bergan, Susan Tsai, Rebecca Aft, Sreeraj Pillai, Mark Watson, Amy K. Kim, Kazuaki Chikamatsu, Masanori Hayashi, David M Loeb, Navin R. Pinto, R. Katherine Alpaugh, Cha-Mei Tang, Thai Huu Ho, Jeffrey R Marks
ABSTRACT / POSTER 3535 ● 265

Comparison of characteristics and outcomes among veterans receiving first-line immunotherapy versus chemotherapy for stage IV non-small cell lung cancer.
SESSION
Publication Only: Health Services Research and Quality Improvement
AUTHOR(S)
Christina D Williams, Lin Gu, Vishal Vashistha, Ashlyn Press, Michael J. Kelley
ABSTRACT e19295

Practice gaps and challenges integrating new immuno-oncology agents in the treatment of cancer patients in the United States: A mixed-method study.
SESSION
Professional Development and Education Advances
AUTHOR(S)
Neal E. Ready, Aparna Raj Parikh, Patrice Lazure, Morgan Peniuta, Marianne Davies, Monica Augustyniak, Jeffrey Caterino, Robert Lewandowski, Alexander J. Lazar, Suzanne Murray
ABSTRACT / POSTER 11028 ● 285

ApricityRx companion digital therapeutic for evidence-based mitigation and phenotype-linked molecular characterization of irAEs in patients receiving immune checkpoint therapy (ICT).
SESSION
Care Delivery and Regulatory Policy
AUTHOR(S)
Matthew T Campbell, Tian Zhang, Lynda Chin, Allison Betof Warner, Matthen Mathew
ABSTRACT / POSTER TPS2089 ● 81

Multiomics profiling of longitudinal melanoma specimens unravels molecular mechanisms of resistance to sequential targeted and cancer immunotherapies.
SESSION
Publication Only: Melanoma/Skin Cancers
AUTHOR(S)
Jinho Lee, Marilyne Labrie, Gen Yong, Todd Camp, Hongli Ma, Megan Grout, Wei Xu, Georgia Beasley, Lynn Mara Schuchter, Suzanne McGettigan, Donald M. O'Rourke, Meenhard Herlyn, Christopher L. Corless, Gordon B. Mills, Gao Zhang
ABSTRACT e22015

A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).
SESSION
Publication Only: Lung Cancer—Non-Small Cell Metastatic
AUTHOR(S)
Suresh S. Ramalingam, Tom Stinchcombe, Gregory James Gerstner, Missak Haigentz, Surya Vangala, Megan Parsi, John W. Heyburn, Victor Kabala, Tuhina Prasad, Andres A. Gutierrez, Jonathan Wade Goldman, ADXS-503 Author's Group
ABSTRACT e21682